ASP Isotopes (NASDAQ:ASPI) Sets New 1-Year Low – Should You Sell?

ASP Isotopes Inc. (NASDAQ:ASPI)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $3.87 and last traded at $3.94, with a volume of 8163811 shares traded. The stock had previously closed at $4.58.

Analyst Ratings Changes

A number of research analysts have recently commented on ASPI shares. Weiss Ratings reissued a “sell (d-)” rating on shares of ASP Isotopes in a report on Wednesday, June 24th. Canaccord Genuity Group reissued a “buy” rating and issued a $11.00 price objective on shares of ASP Isotopes in a research note on Tuesday, April 14th. Two investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $13.00.

ASP Isotopes Stock Performance

The stock has a market cap of $488.49 million, a P/E ratio of -1.87 and a beta of 3.51. The firm has a 50 day moving average of $6.14 and a two-hundred day moving average of $5.82. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.37 and a current ratio of 4.39.

ASP Isotopes (NASDAQ:ASPI) last issued its quarterly earnings results on Wednesday, May 20th. The company reported ($0.22) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.06. ASP Isotopes had a negative return on equity of 112.46% and a negative net margin of 644.40%.The company had revenue of $8.36 million for the quarter, compared to the consensus estimate of $3.68 million.

Insiders Place Their Bets

In other ASP Isotopes news, Director Michael Gorley sold 30,000 shares of the stock in a transaction on Tuesday, June 30th. The shares were sold at an average price of $6.27, for a total value of $188,100.00. Following the completion of the sale, the director directly owned 87,908 shares of the company’s stock, valued at $551,183.16. This represents a 25.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Todd Wider sold 50,000 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $6.25, for a total transaction of $312,500.00. Following the completion of the sale, the director owned 722,247 shares in the company, valued at $4,514,043.75. This represents a 6.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 279,079 shares of company stock valued at $2,049,208 in the last 90 days. 14.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ASPI. Encompass Capital Advisors LLC acquired a new stake in ASP Isotopes during the first quarter worth about $30,551,000. Alyeska Investment Group L.P. increased its stake in ASP Isotopes by 73.4% during the fourth quarter. Alyeska Investment Group L.P. now owns 4,895,546 shares of the company’s stock valued at $26,191,000 after acquiring an additional 2,072,851 shares during the period. Vanguard Group Inc. raised its holdings in ASP Isotopes by 37.9% in the 3rd quarter. Vanguard Group Inc. now owns 4,516,763 shares of the company’s stock valued at $43,451,000 after acquiring an additional 1,241,024 shares in the last quarter. Rovida Investment Management Ltd raised its holdings in ASP Isotopes by 28.1% in the 4th quarter. Rovida Investment Management Ltd now owns 4,100,000 shares of the company’s stock valued at $21,894,000 after acquiring an additional 900,000 shares in the last quarter. Finally, UBS Group AG raised its holdings in ASP Isotopes by 150.3% in the 4th quarter. UBS Group AG now owns 2,406,457 shares of the company’s stock valued at $12,875,000 after acquiring an additional 1,445,165 shares in the last quarter. Institutional investors and hedge funds own 16.80% of the company’s stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.